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Objective. Beta-lactam antibiotics are recommended as first-line for treatment of methicillin-sensitive Staphylococcus aureus 
(MSSA) bacteremia. The objective of this study was to compare effectiveness of anti-MSSA therapies among bacteremia patients 
exclusively exposed to 1 antimicrobial.
Method. This was a national retrospective cohort study of patients hospitalized in Veterans Affairs medical centers with MSSA 
bacteremia from January 1, 2002, to October 1, 2015. Patients were included if they were treated exclusively with nafcillin, oxacillin, 
cefazolin, piperacillin/tazobactam, or fluoroquinolones (moxifloxacin and levofloxacin). We assessed 30-day mortality, time to dis-
charge, inpatient mortality, 30-day readmission, and 30-day S. aureus reinfection. Hazard ratios (HRs) and 95% confidence intervals 
(CI) were calculated using propensity-score (PS) matched Cox proportional hazards regression model.
Results. When comparing nafcillin/oxacillin (n = 105) with cefazolin (n = 107), 30-day mortality was similar between groups 
(PS matched n  =  44; HR, 0.67; 95% CI, 0.11–4.00), as were rates of the other outcomes assessed. As clinical outcomes did not 
vary between nafcillin/oxacillin and cefazolin, they were combined for comparison with piperacillin/tazobactam (n  =  113) and 
fluoroquinolones (n = 103). Mortality in the 30 days after culture was significantly lower in the nafcillin/oxacillin/cefazolin group 
compared with piperacillin/tazobactam (PS matched n  =  48; HR, 0.10; 95% CI, 0.01–0.78), and similar when compared with 
fluoroquinolones (PS matched n = 32; HR, 1.33; 95% CI, 0.30–5.96).
Conclusions. In hospitalized patients with MSSA bacteremia, no difference in mortality was observed between nafcillin/oxa-
cillin and cefazolin or fluoroquinolones. However, higher mortality was observed with piperacillin/tazobactam as compared with 
nafcillin/oxacillin/cefazolin, suggesting it may not be as effective as a monotherapy in MSSA bacteremia.
Key words:  antibiotic treatment; bloodstream infection; comparative effectiveness; methicillin-susceptible Staphylococcus au-
reus; Veterans.
INTRODUCTION
Staphylococcus aureus bacteremia is associated with mor-
tality rates as high as 22%–42% [1, 2]. S.  aureus can metas-
tasize to other organs, including the heart (ie, endocarditis) 
in up to 30%–40% of patients, making appropriate patient 
management crucial for the prevention of infection-related 
complications and mortality [3]. Antistaphylococcal penicillins 
and cefazolin generally are recognized as preferred treatment 
options against MSSA BSIs [4–8]. Furthermore, other beta-
lactams (eg, piperacillin/tazobactam) and fluoroquinolones are 
utilized clinically for methicillin-sensitive Staphylococcus au-
reus (MSSA) bloodstream infections (BSIs), despite the lack of 
data supporting this practice.
Several observational comparative effectiveness studies of 
antistaphylococcal penicillins and cefazolin for the treatment of 
MSSA BSIs have been conducted in the United States, Australia, 
New Zealand, Asia, and Canada, ranging from approximately 
100 to 7300 patients [4–10]. Although 2 studies favor beta-lactam 
therapy over vancomycin for definitive treatment of MSSA BSIs 
[10, 11], effectiveness between cefazolin and antistaphylococcal 
penicillins is harder to elucidate as several studies have found 
no difference in outcomes [4–8] and 2 studies reported better 
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outcomes with cefazolin [9, 12]. A  recent meta-analysis of 7 
studies, analyzing 1589 patients receiving cefazolin and 2802 
patients receiving antistaphylococcal penicillins, reported sig-
nificantly lower 90-day mortality with cefazolin [12]. Similar 
findings were observed in another recent meta-analysis that in-
cluded 10 studies and 4728 patients [13]. However, these findings 
are difficult to interpret due to broad and varying antimicrobial 
treatment definitions, including exposures to various anti-
biotic therapies over the course of infection, which produced 
within-treatment-group heterogeneity in the meta-analysis 
and limited direct comparison between studies. Therefore, the 
objective of this study was to compare effectiveness between 
preferred monotherapy treatments (ie, nafcillin, oxacillin, and 
cefazolin), and alternative monotherapy treatments, including 
piperacillin/tazobactam and fluoroquinolones (levofloxacin 
and moxifloxacin) in patients with MSSA BSI. Our cohort 
uniquely describes patients treated exclusively with 1 of these 
antistaphylococcal antimicrobial agents.
METHODS
Study Design and Patient Population
We identified a retrospective cohort of patients with MSSA-
positive blood cultures that were collected January 1, 2002, 
to October 1, 2015, during a hospital admission at a Veterans 
Affairs (VA) medical center. The following inclusion criteria 
were applied: (1) aged 18  years old or older, (2) remained 
admitted for more than 2 days, and (3) survived for more than 
2  days. The culture collection date served as the index date. 
Antibiotic therapies were assessed from the index date through 
the discharge date or the first 30 days after culture for admissions 
of longer durations. We identified patients treated with a single 
antimicrobial therapy for the duration of treatment. Patients re-
ceiving combination therapy or with a change in therapy were 
excluded. For our study, we identified patients treated with 
nafcillin, oxacillin, cefazolin, piperacillin/tazobactam, or fluor-
oquinolone (moxifloxacin and levofloxacin) monotherapy. To 
eliminate the influence of confounding by comedication, we 
only included patients treated exclusively with these antibiotics 
of interest. Therefore, we excluded patients with changes or 
switches in therapy and also excluded patients with other doses 
of systemic, empiric, or definitive antimicrobial agents.
Clinical data were obtained from national VA databases 
and included International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) diagnostic and 
procedure codes during outpatient visits and inpatient stays, 
microbiologic and chemistry laboratory data, vital signs, and 
pharmacy data, including bar code medication administration 
records [14, 15]. Current and past comorbidities were identified 
from ICD-9-CM codes. The modified Acute Physiology and 
Chronic Health Evaluation (APACHE) III score was utilized to 
assess severity of illness, as previously defined [15]. We assessed 
clinical outcomes including all-cause mortality within 30 days 
of the first positive MSSA blood culture (index date), length of 
hospital stay, length of intensive care unit stay, inpatient mor-
tality, 30-day readmission, and 30-day S. aureus (ie, MSSA and 
methicillin-resistant S. aureus [MRSA]) reinfection.
Statistical Analysis
Differences in patient characteristics that were assessed for 
the following groups compared: (1) nafcillin/oxacillin versus 
cefazolin, (2) nafcillin/oxacillin/cefazolin versus piperacillin/
tazobactam, and (3) nafcillin/oxacillin/cefazolin versus 
moxifloxacin/levofloxacin. Therefore, the following steps 
were repeated for each comparison. Initial assessment of 
differences included chi-square or Fisher exact test for catego-
rical variables, and t test or Wilcoxon rank sum test for con-
tinuous variables. Then likelihood ratio testing was used to 
identify patient characteristics associated with both exposure 
and clinical outcomes. Next, propensity scores (PS) using lo-
gistic regression with backwards stepwise elimination were de-
veloped. Characteristics, including age, sex, severity of illness, 
intensive care stays, and other characteristics independently as-
sociated with both exposure and clinical outcomes, were used 
to build the propensity score model. For each PS model, the ab-
sence of multi-collinearity and goodness of fit were confirmed. 
We identified matches using nearest neighbor matching within 
a caliper of 0.05. Hazard ratios (HRs) and 95% confidence 
intervals (CIs) were calculated using Cox proportional hazards 
regression model. A sensitivity analysis adjusting Cox models 
for propensity score quintiles was performed. Analyses were 
performed with SAS software v. 9.2 (SAS Institute, Cary, NC).
RESULTS
A total of 428 patients were identified and met final inclusion 
criteria for analysis. Of them, 105 were in the nafcillin or oxa-
cillin group (24.5%), 107 in the cefazolin group (25.0%), 113 in 
the piperacillin/tazobactam (26.4%), and 103 in the fluoroquin-
olone group (24.1%). We first compared nafcillin/oxacillin with 
cefazolin (Table 1). The Charlson comorbidity index was similar 
between the nafcillin/oxacillin and cefazolin groups (median, 2 
vs 2; P = .61); however, patients in the cefazolin group had higher 
rates of chronic kidney disease (41.1% vs 27.6%; P = .04), older age 
(mean, 64 vs 60.3; P = .03), and earlier antimicrobial treatment ini-
tiation from culture (median, 1 vs 2 days; P = .009) when compared 
with nafcillin/oxacillin. Baseline characteristics were balanced be-
tween the nafcillin/oxacillin and cefazolin groups via propensity 
score matching (nafcillin/oxacillin n = 44, cefazolin n = 44). All 
clinical outcomes were similar between the exposure groups, in-
cluding 30-day mortality (HR, 0.67; 95% CI, 0.11–4.00), discharge 
(HR, 0.80; 95% CI, 0.44–1.44) and 30-day readmission (HR, 0.75; 
95% CI, 0.26–2.16) (Figure 1). Consequently, the nafcillin/oxa-
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treatment options with piperacillin/tazobactam (n  =  113) and 
fluoroquinolones (n = 103), respectively.
The piperacillin/tazobactam group (n = 113), compared with 
the nafcillin/oxacillin/cefazolin group (n = 212), was older (66.6 
vs 62.2 years, P = .003), with higher comorbidity scores (3 vs 2, 
P = .0001) and APACHE scores (34.5 vs 24.0, P < .0001; Table 
2). Intensive care unit admissions (13.3% vs 5.2%, P = .01), and 
previous hospitalizations (24.8% vs 15.1%, P = .03) were more 
common in the piperacillin/tazobactam group, with significant 
variations in infection source. These baseline characteristics 
Table 1. Baseline Demographic and Clinical Characteristics of Patients Receiving Cefazolin and Nafcillin/Oxacillin Therapy
Characteristics
Overall cohort Propensity-score matched cohort
Cefazolin (n = 107)
Nafcillin or  
oxacillin (n = 105) P value Cefazolin (n = 44)
Nafcillin or  
oxacillin (n = 44) P value
Age, years, mean ± SD 64.0 ± 12.8 60.3 ± 12.4 .03 60.8 ± 13.3 62.3 ± 12.3 .57
Male sex, n (%) 105 (98.1) 103 (98.1) 1.0 43 (97.7) 43 (97.7) 1.0
Body mass index, kg/m2, mean ± SD 27.9 ± 7.0 28.0 ± 7.3 .95 27.6 ± 7.9 27.6 ± 7.5 .99
Obese, n (%) 41 (38.3) 35 (33.3) .45 14 (31.8) 16 (36.4) .65
Year of treatment       
2002–2009, n (%) 78 (72.9) 86 (81.9) .12 36 (81.8) 37 (84.1) .78
2010–2015, n (%) 29 (27.1) 19 (18.1) .12 8 (18.2) 7 (15.9) .78
Charlson comorbidity index, median (IQR) 2 (1–4) 2 (1–4) .61 2 (1–4) 3 (1.5–4) .51
Comorbidities, n (%)       
Alcoholism 11 (10.3) 15 (14.3) .37 5 (11.4) <5 (<11.4) 1.0
Cancer 11 (10.3) 13 (12.4) .63 <5 (<11.4) <5 (<11.4) 1.0
Cardiac arrhythmias 27 (25.2) 21 (20.0) .36 10 (22.7) 10 (22.7) 1.0
Cerebrovascular disease 8 (7.5) 13 (12.4) .23 <5 (<11.4) 5 (11.4) .43
Diabetes mellitus, complicated 20 (18.7) 13 (12.4) .21 7 (15.9) 5 (11.4) .53
Diabetes mellitus, uncomplicated 31 (29.0) 41 (39.1) .12 13 (29.6) 21 (47.7) .08
Chronic kidney disease 44 (41.1) 29 (27.6) .04 18 (40.9) 18 (40.9) 1.0
Dialysis 13 (12.2) 17 (16.2) .40 8 (18.2) 12 (27.3) .31
Chronic respiratory disease 17 (15.9) 15 (14.3) .74 7 (15.9) 10 (22.7) .42
Coagulopathy <5 (<4.7) <5 (<4.8) 1.0 <5 (<11.4) <5 (<11.4)  1.0
Coronary heart disease 35 (32.7) 39 (37.1) .50 13 (29.6) 17 (38.6) .37
Congestive heart failure 18 (16.8) 15 (14.3) .61 8 (18.2) 7 (15.9) .78
Fluid and electrolyte disorders 23 (21.5) 27 (25.7) .47 10 (22.7) 6 (13.6) .27
Hypertension 65 (60.8) 60 (57.1) .59 26 (59.1) 28 (63.6) .66
Peripheral vascular disease 16 (14.9) 11 (10.5) .33 5 (11.4) <5 (<11.4) 1.0
Liver disease 9 (8.4) 16 (15.2) .12 5 (11.4) 7 (15.9) .53
Community onset infection,b n (%) 78 (72.9) 75 (71.4) .81 34 (77.3) 35 (79.6) .79
Intensive care admission, n (%) 5 (4.7) 6 (5.7) .73 <5 (<11.4) <5 (<11.4)  1.0
Sepsis, n (%) 11 (10.3) <5 (<4.8) .07 <5 (<11.4) <5 (<11.4) 1.0
APACHE score,b median (IQR) 25.5 (17–37) 22 (14–34) .06 23 (15–33) 20 (13–37) .55
Source of infection,c n (%)       
Endocarditis 7 (6.5) 8 (7.6) .76 <5 (<11.4) <5 (<11.4) .68
Skin and soft tissue infections 28 (26.2) 18 (17.1) .11 12 (27.3) 10 (22.7) .62
Osteomyelitis 12 (11.2) 14 (13.3) .64 6 (13.6) 6 (13.6) 1.0
Urine <5 (<4.7) 8 (7.6) .06 0 5 (11.4) .06
Respiratory <5 (<4.7) <5 (<4.8) .68 <5 (<11.4) <5 (<11.4) 1.0
Surgical site 6 (5.6) <5 (<4.8) .28 <5 (<11.4) <5 (<11.4) 1.0
Chronic ulcer 8 (7.5) <5 (<4.8) .25 <5 (<11.4) <5 (<11.4) 1.0
Prior healthcare exposures, n (%)       
Hospitalization prior 30d 14 (13.1) 18 (17.1) .41 6 (13.6) 6 (13.6) 1.0
Nursing home prior 30d <5 (<4.7) <5 (<4.8) 1.0 0 0 —
Time to antimicrobial initiation from culture, 
median days (IQR)
1 (0–3) 2 (0–4) .009 2 (0.5–3.5) 2.5 (0–4) .68
Inpatient antimicrobial duration, median 
days (IQR)
8 (5–14) 9 (6–16) .14 7 (4–14) 7 (5–16) .41
Abbreviations: APACHE, acute physiology and chronic health evaluation; IQR, interquartile range; SD, standard deviation.
aCulture-confirmed source of infection.
bWith missing values.
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were balanced via a propensity score model (nafcillin/oxacillin/
cefazolin n = 48, piperacillin/tazobactam n = 48) and are fur-
ther detailed in Table 2. In the propensity-score matched co-
hort, time to 30-day mortality was significantly higher in the 
piperacillin/tazobactam group than the preferred treatment 
group (HR, 0.10; 95% CI, 0.01–0.78; Figure 2). Although time 
to antimicrobial initiation from culture and duration of therapy 
were included in the propensity score model, they remained 
significantly different in the matched groups. In a sensitivity 
analysis, inclusion of these variables in the Cox proportional 
hazards model did not change the effect estimates.
Comorbidity burden was similar between the fluoroquino-
lone group (moxifloxacin and levofloxacin n = 103) and the pre-
ferred treatment group (nafcillin/oxacillin/cefazolin n  =  212; 
Table 3). However, fluoroquinolone-treated patients were older 
(69 vs 62.2  years, P  <  .0001), with higher APACHE scores 
(32 vs 24, P  =  .0002). After balancing patient characteristics 
(nafcillin/oxacillin/cefazolin n = 32, moxifloxacin/levofloxacin 
n = 32), no differences in time to mortality were observed be-
tween fluoroquinolones and nafcillin/oxacillin/cefazolin in the 
propensity-score matched cohort (HR, 1.33; 95% CI, 0.30–5.96; 
Figure 2). Similar results across all comparison groups were 
observed in sensitivity analyses adjusted by propensity score 
quintiles (Supplementary Tables S1 to S3).
DISCUSSION
We compared clinical outcomes among patients with MSSA 
bacteremia exclusively treated with nafcillin/oxacillin, cefazolin, 
piperacillin/tazobactam, or fluoroquinolone monotherapy 
during their hospital stay. Overall, our findings are similar to 
published observational studies, with additional insight re-
garding the use piperacillin/tazobactam in MSSA bacteremia.
Similar to previously published observational studies, we 
found that cefazolin effectiveness was not significantly different 
from antistaphylococcal penicillins (ie, cloxacillin, flucloxacillin, 
and nafcillin) [4, 5, 7, 8]. In contrast with our findings, sev-
eral studies have reported improved clinical outcomes with 
cefazolin [9, 12, 13]. This discrepancy may be due to differences 
in inclusion criteria surrounding antimicrobial exposure during 
treatment, including safety as an outcome and a potential inoc-
ulum effect. Our study preselected a unique cohort of patients 
that received only nafcillin/oxacillin, cefazolin, piperacillin/
tazobactam, or fluoroquinolones throughout their entire 
hospitalization.
A retrospective cohort conducted in the VA population 
compared mortality among MSSA bacteremia patients re-
ceiving definitive treatment with nafcillin or oxacillin (n = 2004) 
versus cefazolin (n = 1163) from 2003–2010 [9]. In contrast to 
our study, the authors found that mortality was higher in the 
nafcillin/oxacillin group versus the cefazolin group at 30 days 
(10% vs 15%; adjusted HR, 0.63; 95% CI, 0.51–0.78; P < .001), 
and at 90 days (25% vs 20%; adjusted HR, 0.77; 95% CI, 0.66–
0.90; P = .001), concluding that cefazolin may be preferred over 
nafcillin/oxacillin. The reason for the differences between our 
study and this study may be a result of the additional antibiotics 
used during both empiric therapy and concomitant antibi-
otic use. In this other VA study, definitive therapy was defined 
as receipt of nafcillin, oxacillin, or cefazolin between 4 and 
14  days after culture collection. This treatment definition did 
not account for empiric therapy or concomitant therapy [9, 11]. 
Further, it is unclear whether patients receiving as little as 1 day 
of nafcillin, oxacillin, or cefazolin were included in these treat-
ment groups as duration of therapy was not discussed in the 
article.
A recently published meta-analysis, which included studies 
utilizing various definitions of definitive treatment, found 
that 90-day mortality was less likely in patients who re-
ceived cefazolin compared with antistaphylococcal penicillins 
(nafcillin, oxacillin, or cloxacillin; odds ratio [OR], 0.63; 95% 
CI, 0.41–0.99) [12]. However, the limitations of this meta-
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Figure 1. Clinical Outcomes in Propensity-Matched Cefazolin-Treated and Nafcillin/Oxacillin-Treated Patients With Methicillin-Susceptible Staphylococcus aureus 
Bacteremiaa.a The propensity score was derived from an unconditional logistic regression model and controlled for the variables listed in Supplementary Table S4. The as-
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clinical practice. For example, only 2 of the 7 included studies 
identified a decreased risk of mortality with cefazolin. One was 
a small, prospective observational study conducted in South 
Korea that reported a higher discontinuation rate with nafcillin 
due to side effects. The second study that found a reduction in 
mortality with cefazolin was the aforementioned 2003–2010 
VA study [9] that utilized broad exposure definitions. This was 
the largest and most heavily weighted study included in the 
Table 2. Baseline Demographic and Clinical Characteristics of Patients Receiving Piperacillin/Tazobactam and Nafcillin/Oxacillin/Cefazolin Therapy
Characteristics




Nafcillin or oxacillin or 
cefazolin (n = 212) P value
Piperacillin/ 
tazobactam (n = 48)
Nafcillin or oxacillin or 
cefazolin (n = 48) P value
Age, years, mean ± SD 66.6 ± 12.9 62.2 ± 12.7 .003 64.4 ± 13.8 63.3 ± 13.0 .69
Male sex, n (%) 111 (98.2) 208 (98.1) 1.0 48 (100) 47 (97.9) 1.0
Body mass index, kg/m2, mean ± SD 26.9 ± 7.2 27.9 ± 7.1 .21 26.8 ± 7.6 27.0 ± 6.0 .90
Obese, n (%) 38 (33.6) 76 (35.9) .69 16 (33.3) 16 (33.3) 1.0
Year of treatment       
2002–2009, n (%) 76 (67.3) 164 (77.4) .05 36 (75.0) 36 (75.0) 1.0
2010–2015, n (%) 37 (32.7) 48 (22.6) .05 12 (25.0) 12 (25.0) 1.0
Charlson comorbidity index, median (IQR) 3 (2–5) 2 (1–4) .0001 3 (2–4) 2 (1–5) .34
Comorbidities, n (%)       
Alcoholism 12 (10.6) 26 (12.3) .66 7 (14.6) 7 (14.6) 1.0
Cancer 22 (19.5) 24 (11.3) .05 8 (16.7) 7 (14.6) .78
Cardiac arrhythmias 21 (18.6) 48 (22.6) .39 7 (14.6) 7 (14.6) 1.0
Cerebrovascular disease 9 (8.0) 21 (9.9) .56 5 (10.4) <5 (<10.4) 1.0
Diabetes mellitus, complicated 37(32.7) 33 (15.6) .0003 13 (27.1) 10 (20.8) .47
Diabetes mellitus, uncomplicated 48 (42.5) 72 (34.0) .13 19 (39.6) 17 (35.4) .67
Chronic kidney disease 41 (36.3) 73 (34.4) .74 14 (29.2) 16 (33.3) .66
Dialysis 7 (6.2) 30 (14.2) .03 <5 (<10.4) 5 (10.4) .71
Chronic respiratory disease 22 (19.5) 32 (15.1) .31 5 (10.4) 6 (12.5) .75
Coagulopathy 10 (8.9) 8 (3.8) .06 5 (10.4) <5 (<10.4) .44
Coronary heart disease 29 (25.7) 74 (34.9) .09 12 (25.0) 11 (22.9) .81
Congestive heart failure 26 (23.0) 33 (15.6) .10 9 (18.8) 5 (10.4) .25
Fluid and electrolyte disorders 42 (37.2) 50 (23.6) .01 12 (25.0) 14 (29.2) .65
Hypertension 76 (67.3) 125 (59.0) .14 34 (70.8) 30 (62.5) .39
Peripheral vascular disease 24 (21.2) 27 (12.7) .04 10 (20.8) 5 (10.4) .16
Liver disease 10 (8.9) 25 (11.8) .42 5 (10.4) <5 (<10.4) .71
Community onset infection,b n (%) 81 (71.7) 153 (72.2) .93 33 (68.8) 36 (75.0) .50
Intensive care admission, n (%) 15 (13.3) 11 (5.2) .01 <5 (<10.4) <5 (<10.4) .36
Sepsis, n (%) 8 (7.1) 15 (7.1) .99 <5 (<10.4)  8 (16.7) .03
APACHE score,b median (IQR) 34.5 (22–52) 24.0 (15–37) <.0001 31 (18–44) 24 (18–38) .27
Source of infection,c n (%)       
Endocarditis 0 15 (7.1) .004 0 <5 (<10.4) .24
Skin and soft tissue infections 38 (33.6) 46 (21.7) .02 16 (33.3) 16 (33.3) 1.0
Osteomyelitis 13 (11.5) 26 (12.3) .84 6 (12.5) 9 (18.8) .40
Urine 13 (11.5) 10 (4.7) .02 <5 (<10.4) <5 (<10.4) 1.0
Respiratory 10 (8.9) 6 (2.8) .02 <5 (<10.4) <5 (<10.4) 1.0
Surgical site <5 (<4.4) 8 (3.8) .50 <5 (<10.4) <5 (<10.4) .36
Chronic ulcer 24 (21.2) 12 (5.7) <.0001 9 (18.8) 6 (12.5) .40
Prior healthcare exposures, n (%)       
Hospitalization prior 30d 28 (24.8) 32 (15.1) .03 16 (33.3) 12 (25.0) .37
Nursing home prior 30d <5 (<4.4) <5(<2.4) .61 <5 (<10.4) <5 (<10.4) 1.0
Time to antimicrobial initiation from cul-
ture, median days (IQR)
0 (0–1) 2 (0–4) <.0001 0 (0–1) 1 (0–2) .02
Inpatient antimicrobial duration, median 
days (IQR)
5 (3–9) 8.5 (5–14.5) <.0001 5 (3–10) 10.5 (5–17.5) .001
Abbreviations: APACHE, acute physiology and chronic health evaluation; IQR, interquartile range; SD, standard deviation.
aCulture-confirmed source of infection.
bWith missing values.








hode Island Library user on 26 July 2019
6 • ofid • Beganovic et al
meta-analysis, accounting for 73.2% of the cefazolin patients 
and 71.5% of the antistaphylococcal penicillin [12]. A second 
meta-analysis evaluated 10 studies with similar results and 
limitations; however, a subgroup analysis excluding the 2010 
VA study [9] was performed and a mortality benefit favoring 
cefazolin over antistaphylococcal penicillins remained (risk 
ratio [RR], 0.74; 95% CI, 0.58–0.94) [13]. Our study differed, 
as we exclusively assessed monotherapy, presuming that em-
piric and concomitant therapies influence clinical outcomes. 
Differences in exposure definitions across studies make direct 
comparisons challenging and contribute to the limited applica-
bility of the meta-analysis results.
Although our study did not evaluate safety, it is important to 
note that in addition to cefazolin demonstrating greater safety 
compared with nafcillin/oxacillin in several studies [6, 16–24], 
nafcillin treatment may be associated with higher adverse events 
rates than oxacillin [25, 26]. Conversely, increased 30-day all-
cause mortality with cefazolin has been reported in high in-
oculum MSSA infections compared with standard inoculum 
infections (risk ratio [RR], 2.65; 95% CI, 1.10–6.42; P  =  .03) 
[27]. This is likely due to S. aureus beta-lactamase production. 
Initially recognized in the late 1960s with 4 distinct serotypes 
(A, B, C, and D) expressing blaZ enzymes [28, 29], type A blaZ 
appears to have high affinity for deactivating cefazolin via hy-
drolysis. Although hydrolysis may be overcome in standard 
infections (ie, 5  ×  105 CFU/mL), treatment failure in high-
inoculum infections (ie, >5 × 107 CFU/mL) has been described 
[27, 30, 31]. Therefore, inoculum effect (ie, complicated 
bacteremia, with foci of infection) should be considered in 
patients that are not clinically improving or are decompensating 
while on cefazolin [27, 32]. Additionally, the presence of type A, 
B, C, and D blaZ enzymes vary geographically and should be 
considered when selecting an antistaphylococcal penicillin over 
cefazolin. We only assessed patients without changes in therapy 
and, therefore, included patients who tolerated monotherapy 
with nafcillin, oxacillin, cefazolin, piperacillin/tazobactam, or 
fluoroquinolones without significant adverse effects leading to 
treatment discontinuation.
Of interest, 30-day mortality was significantly higher for 
patients receiving piperacillin/tazobactam compared with 
nafcillin, oxacillin, or cefazolin in our study. Our findings are 
consistent with a previously published retrospective single-
center cohort study evaluating empiric and definitive therapy 
for MSSA bacteremia among patients receiving a beta-lactam 
antimicrobial therapy within 48 hours after blood cul-
ture collection [33]. Investigators from this non-US–based 
study identified higher mortality among patients receiving 
beta-lactams/beta-lactam inhibitors (BLBLIs) empirically 
for MSSA bacteremia (OR, 2.68; 95% CI, 1.23–5.85) [33]. 
Based on empiric therapy, they observed a mortality ben-
efit in patients initially treated with oxacillin or cefazolin 
compared with cefuroxime, ceftriaxone, or cefotaxime. For 
definitive therapy, it was concluded that cefazolin was not 
significantly different from oxacillin (OR, 0.91; 95% CI, 
0.47–1.77). Overall, their observations indicate that although 
cefazolin may be a safe and effective alternative to oxacillin, 
30-day mortality
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Figure 2. Clinical Outcomes in Propensity-Matched Nafcillin/Oxacillin/Cefazolin-Treated and Piperacillin/Tazobactam- or Fluoroquinolone-Treated Patients With Methicillin-
Susceptible Staphylococcus aureus Bacteremiaa. aThe propensity score was derived from an unconditional logistic regression model and controlled for the variables listed in 
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other beta-lactams, including second and third generation 
cephalosporins and BLBLIs, may be associated with higher 
mortality. Although conflicting data exist [34, 35], other 
studies have observed poor outcomes associated with second 
and third generation cephalosporins [36–38].
A possible explanation for the increased mortality we 
observed with piperacillin/tazobactam may be due to the in-
ability of tazobactam to induce staphylococcal types A and C 
beta-lactamases, both of which are associated with elevated 
minimum inhibitory concentrations (MIC), in addition to 
Table 3. Baseline Demographic and Clinical Characteristics of Patients Receiving Fluoroquinolones and Nafcillin/Oxacillin/Cefazolin Therapy
Characteristics
Overall cohort Propensity-score matched cohort
Moxifloxacin or 
levofloxacin (n = 103)
Nafcillin or oxacillin 
or cefazolin (n = 212) P value
Moxifloxacin or 
levofloxacin (n = 32)
Nafcillin or oxacillin or 
cefazolin (n = 32) P value
Age, years, mean ± SD 69.0 ± 13.7 62.2 ± 12.7 <.0001 71.3 ± 13.7 67.1 ± 15.3 .25
Male sex, n (%) 100 (97.1) 208 (98.1) .69 32 (100) 30 (93.8) .49
Body mass index, kg/m2, mean ± SD 27.0 ± 7.0 27.9 ± 7.1 .30 27.0 ± 6.4 28.7 ± 7.5 .34
Obese, n (%) 27 (26.2) 76 (35.9) .09 9 (28.1) 11 (34.4) .59
Year of treatment       
2002–2009, n (%) 86 (83.5) 164 (77.4) .21 28 (87.5) 26 (81.3) .49
2010–2015, n (%) 17 (16.5) 48 (22.6) .21 <5 (<15.6) 6 (18.8) .49
Charlson comorbidity index, median (IQR) 2 (1–5) 2 (1–4) .36 2.5 (2–5) 2.5 (1.5–4.5) .55
Comorbidities, n (%)       
Alcoholism 9 (8.7) 26 (12.3) .35 <5 (<15.6) <5 (<15.6) 1.0
Cancer 21 (20.4) 24 (11.3) .03 6 (18.8) 7 (21.9) .76
Cardiac arrhythmias 28 (27.2) 48 (22.6) .38 10 (31.3) 11 (34.4) .79
Cerebrovascular disease 14 (13.6) 21 (9.9) .33 8 (25.0) <5 (<15.6) .10
Diabetes mellitus, complicated 19 (18.5) 33 (15.6) .52 <5 (<15.6) 6 (18.8) .49
Diabetes mellitus, uncomplicated 32 (31.1) 72 (34.0) .61 12 (37.5) 11 (34.4) .79
Chronic kidney disease 24 (23.3) 73 (34.4) .04 11 (34.4) 12 (37.5) .79
Dialysis 7 (6.8) 30 (14.2) .06 <5 (<15.6) 5 (15.6) .71
Chronic respiratory disease 39 (37.9) 32 (15.1) <.0001 10 (31.3) 6 (18.8) .25
Coagulopathy <5 (<4.9) 8 (3.8) .28 0 <5 (<15.6) 1.0
Coronary heart disease 34 (33.0) 74 (34.9) .74 13 (40.6) 12 (37.5) .80
Congestive heart failure 19 (18.5) 33 (15.6) .52 9 (28.1) 8 (25.0) .78
Fluid and electrolyte disorders 39 (37.9) 50 (23.6) .01 10 (31.3) 11 (34.4) .79
Hypertension 55 (53.4) 125 (59.0) .35 21 (65.6) 18 (56.3) .44
Peripheral vascular disease 9 (8.7) 27 (12.7) .30 6 (18.8) 5 (15.6) .74
Liver disease 7 (6.8) 25 (11.8) .17 <5 (<15.6) <5 (<15.6) 1.0
Community onset infection,b n (%) 76 (73.8) 153 (72.2) .76 22 (68.8) 19 (59.4) .43
Intensive care admission, n (%) <5 (<4.9) 11 (5.2) .56 <5 (<15.6) <5 (<15.6) 1.0
Sepsis, n (%) <5 (<4.9) 15 (7.1) .26 <5 (<15.6) <5 (<15.6) 1.0
APACHE score,b median (IQR) 32 (23- 40) 24 (15–37) .0002 29 (21- 38) 30 (18–44) .95
Source of infection,c n (%)       
Endocarditis 0 15 (7.1) .003 0 <5 (<15.6) .49
Skin and soft tissue infections 14 (13.6) 46 (21.7) .09 <5 (<15.6) <5 (<15.6) .67
Osteomyelitis <5 (<4.9) 26 (12.3) .0008 0 <5 (<15.6) .11
Urine 19 (18.5) 10 (4.7) <.0001 <5 (<15.6) <5 (<15.6) 1.0
Respiratory 22 (21.4) 6 (2.8) <.0001 <5 (<15.6) <5 (<15.6) 1.0
Surgical site <5 (<4.9) 8 (3.8) .28 0 0 —
Chronic ulcer 8 (7.8) 12 (5.7) .47 <5 (<15.6) <5 (<15.6) 1.0
Prior healthcare exposures, n (%)       
Hospitalization prior 30d 15 (14.6) 32 (15.1) .90 6 (18.8) 5 (15.6) .74
Nursing home prior 30d <5 (<4.9) <5 (<2.4) 1.0 0 0 —
Time to antimicrobial initiation from cul-
ture, median days (IQR)
0 (0–1) 2 (0–4) <.0001 1 (0–3) 1.5 (0–3.5) .35
Inpatient antimicrobial duration, median 
days (IQR)
5 (3–8) 8.5 (5–14.5) <.0001 5 (4–11.5) 7 (5–10) .27
Abbreviations: APACHE, acute physiology and chronic health evaluation; IQR, interquartile range; SD, standard deviation.
aCulture-confirmed source of infection.
bWith missing values.
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an inoculum effect [32, 39, 40]. A recent study evaluated 302 
MSSA isolates and found increased MICs with increased bac-
terial inoculum [32]. MICs exceeded susceptibility breakpoints 
among BLBLIs, including piperacillin/tazobactam, with sig-
nificant increases in mean MIC between high and standard 
inocula (high inoculum, 48.14  ±  4.08 vs standard inoculum, 
2.04 ± 0.08 mg/L; P < .001). The inoculum effect for piperacillin/
tazobactam exposure also is associated with presence of type 
C blaZ beta-lactamase enzymes 87.8% of the time versus 8.8% 
non-type C (P < .001) [32]. Type C enzymes bind more tightly 
to piperacillin/tazobactam than type A enzymes and can lead to 
a subsequently more pronounced deactivation [40]. Prevalence 
of type C enzymes are as high as 46%–53% nationally and inter-
nationally [31, 41].
Interestingly, we did not observe a difference between 
nafcillin, oxacillin, or cefazolin when compared with 
fluoroquinolones (levofloxacin and moxifloxacin). Studies 
evaluating fluoroquinolones for MSSA bacteremia are limited, 
and often evaluate MRSA [42, 43], which is not a recommended 
treatment option [44]. A  prospective, randomized, open-
label multicenter trial that compared an oral fluoroquinolone 
(fleroxacin) plus rifampin to standard therapy (parenteral 
flucoxacillin or vancomycin) for staphylococcal infections 
(not exclusively MSSA), found that oral treatment was sim-
ilar to parenteral therapy [43]. Although this may be be-
cause fluoroquinolones have excellent oral bioavailability and 
tissue penetration, the comparator in this study is not a pre-
ferred treatment for MSSA [43]. Safety concerns should be 
considered prior to selecting fluoroquinolones as a treatment 
for MSSA bacteremia, including the high risk of developing 
a Clostridiodes difficile infection [45], as well as manufacturer 
and Food and Drug Administration (FDA)-recognized adverse 
events, including, but not limited to, tendon rupture, aortic rup-
ture, psychiatric effects, and hypoglycemia. Consequently, the 
use of fluoroquinolones should be avoided when alternative 
agents are available.
Our study is not without limitations. We only included 
patients with exposure to 1 antimicrobial agent throughout 
their entire hospitalization. This is not representative of typ-
ical clinical scenarios where changes in treatment occur when 
moving from empiric to definitive therapy and where combi-
nation therapy may be used [46]. In fact, antibiotic treatment 
may be misclassified in as many as 86% of patients when tra-
ditional exposure definitions are used [46]. Therefore, our ex-
posure definition allowed us to attribute clinical outcomes to 
a single antibiotic, rather than overlooking other antibiotic 
exposures, including varying periods of combination therapy, 
overlapping therapy, and changes in therapy, which commonly 
occurs in other studies. A  known limitation of observational 
studies is the inability to control for all factors that contribute 
to confounding by indication, as providers might not typically 
initiate nafcillin or oxacillin therapy empirically. Confounding 
by comedication is a major concern with existing compara-
tive effectiveness research in infectious diseases. We, there-
fore, utilized a highly specific exposure definition to overcome 
this problem. However, because antibiotic monotherapy was 
not commonly used, sample sizes were low for some of the 
exposure-outcome associations assessed. This resulted in sev-
eral wide confidence interval ranges, which affected the ability 
to detect small differences between groups. Moreover, informa-
tion on source control, time to blood culture clearance, total du-
ration of therapy, doses used, and routes of administration for 
fluoroquinolones (ie, intravenous versus oral) were not avail-
able. Our findings are supported by other published studies 
that have concluded cefazolin is similar to antistaphylococcal 
penicillins, and piperacillin/tazobactam may be sub-optimal to 
treat MSSA bacteremia [4, 5, 7, 8, 10].
S.  aureus bacteremia can metastasize, making it difficult 
to eradicate and leading to high mortality rates [1, 2]. Our 
comparative effectiveness study demonstrated similar clin-
ical outcomes between nafcillin, oxacillin, cefazolin, and 
fluoroquinolones. However, 30-day mortality was higher in 
patients receiving piperacillin/tazobactam monotherapy. This 
observed higher mortality may be a result of the beta-lactam 
inoculum effect providing clinical relevance of this phenom-
enon previously described by in vitro data [32]. We observed 
higher mortality rates among patients treated exclusively with 
piperacillin-tazobactam, suggesting it may not be as effec-
tive as monotherapy in MSSA bacteremia. Further studies are 
warranted to guide provider decisions regarding empiric and 
definitive therapy in MSSA bacteremia, including the effect of 
discontinuation of piperacillin-tazobactam as empiric therapy.
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